Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:ASLN NASDAQ:OASM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.39-1.8%$4.23$2.93▼$7.55$560.14M1.461.85 million shs7.38 million shsASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/AOASMOasmia Pharmaceutical AB (publ)$1.46$0.94▼$5.70$375K0.9698,414 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics-10.51%-4.79%+9.56%+11.19%+37.54%ASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%0.00%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%0.00%0.00%-75.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.39-1.8%$4.23$2.93▼$7.55$560.14M1.461.85 million shs7.38 million shsASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/AOASMOasmia Pharmaceutical AB (publ)$1.46$0.94▼$5.70$375K0.9698,414 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics-10.51%-4.79%+9.56%+11.19%+37.54%ASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%0.00%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%0.00%0.00%-75.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$8.5093.62% UpsideASLNASLAN Pharmaceuticals 0.00N/AN/AN/AOASMOasmia Pharmaceutical AB (publ) 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OASM, AQST, and ASLN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026AQSTAquestive Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.004/20/2026AQSTAquestive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$44.54M12.36N/AN/A($0.28) per share-15.68ASLNASLAN Pharmaceuticals$12M0.10N/AN/A($6.50) per share-0.09OASMOasmia Pharmaceutical AB (publ)$220K0.00N/AN/A$0.63 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$83.78M-$0.61N/AN/AN/A-137.08%N/A-49.33%8/10/2026 (Estimated)ASLNASLAN Pharmaceuticals-$44.22M-$21.92N/AN/AN/AN/A-8,454.87%-121.60%N/AOASMOasmia Pharmaceutical AB (publ)-$18.95MN/AN/AN/AN/A-8,633.64%-43.94%-28.92%N/ALatest OASM, AQST, and ASLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026AQSTAquestive Therapeutics-$0.14-$0.07+$0.07-$0.07$10.90 million$14.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A4.103.85ASLNASLAN PharmaceuticalsN/A1.051.05OASMOasmia Pharmaceutical AB (publ)N/A0.800.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%ASLNASLAN Pharmaceuticals58.82%OASMOasmia Pharmaceutical AB (publ)0.11%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics6.81%ASLNASLAN Pharmaceuticals4.69%OASMOasmia Pharmaceutical AB (publ)N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics160125.45 million116.91 millionOptionableASLNASLAN Pharmaceuticals302.04 million1.95 millionNo DataOASMOasmia Pharmaceutical AB (publ)5774.97 millionN/ANot OptionableOASM, AQST, and ASLN HeadlinesRecent News About These CompaniesDouble Bond Pharmaceutical International AB (DBPHAb)October 31, 2024 | investing.comSector-Health Care & PharmaceuticalsMay 17, 2024 | newsweek.comNBOEUF Bonesupport Holding AB (publ)April 30, 2024 | seekingalpha.comLipigon Pharmaceuticals AB LPGOMarch 22, 2024 | morningstar.comMLSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call TranscriptMarch 6, 2024 | gurufocus.comOasmia Pharmaceutical AB (publ) - Special Call TranscriptMarch 6, 2024 | gurufocus.comResurs Holding AB (publ) (RESURS.ST)February 7, 2024 | finance.yahoo.comQuiaPEG Pharmaceuticals Holding AB QUIAJanuary 6, 2024 | morningstar.comMNewbury Pharmaceuticals AB (NEWBRY)November 29, 2023 | investing.comDentsu Creative bags mandate for Torrent Pharmaceuticals’ Shelcal & UnienzymeSeptember 26, 2023 | bestmediainfo.comBLipigon Pharmaceuticals AB (LPGO)September 14, 2023 | investing.comSpeqta publ AB (SPEQT)August 25, 2023 | investing.comPRXXF Paradox Interactive AB (publ)August 25, 2023 | seekingalpha.comNotice of annual general meeting in Alzinova AB (publ)April 25, 2023 | privataaffarer.sePReport from Annual General Meeting 2023 of PowerCell Sweden AB (publ)April 21, 2023 | privataaffarer.sePNotice of Annual General Meeting 2023 in Enzymatica AB (publ) (2)April 2, 2023 | europapress.esEOXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2MFebruary 26, 2023 | seekingalpha.comUS regulators clear way for more monkeypox vaccine shipmentsJuly 14, 2022 | starherald.comSPRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE (MFN)March 24, 2022 | avanza.seAOasmia expands R&D ability with planned laboratory upgradeMarch 17, 2022 | privataaffarer.sePNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOASM, AQST, and ASLN Company DescriptionsAquestive Therapeutics NASDAQ:AQST$4.39 -0.08 (-1.79%) Closing price 04:00 PM EasternExtended Trading$4.38 -0.01 (-0.32%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.ASLAN Pharmaceuticals NASDAQ:ASLN$0.60 0.00 (0.00%) As of 06/25/2026ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.Oasmia Pharmaceutical AB (publ) NASDAQ:OASMOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
